US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

Articles published by Alumis Inc.

News headline image
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
From Alumis Inc.
Via GlobeNewswire
Tickers ALMS
News headline image
Alumis to Participate in Upcoming September Investor Conferences
From Alumis Inc.
Via GlobeNewswire
Tickers ALMS
News headline image
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
From Alumis Inc.
Via GlobeNewswire
Tickers ALMS
News headline image
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
From Alumis Inc.
Via GlobeNewswire
Tickers ALMS
News headline image
Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis
From Alumis Inc.
Via Business Wire
News headline image
Alumis Appoints Jörn Drappa M.D., Ph.D., as Chief Medical Officer and Roman G. Rubio, M.D., as Senior Vice President, Clinical Development and Translational Medicine
From Alumis Inc.
Via Business Wire